New
Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
ETF What's Up
Don’t Miss a Move in the ETF Market
Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.
ARKG ETF · ARK Genomic Revolution ETF
The ARKG Exchange Traded Fund (ETF) is provided by Ark Investment. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.
Last update Yesterday at 1:30 PM UTC
LIVE
CLOSED
This fund is part ofBioTech & Genomics1M perf.-1.26%
Last price
$27.67
1M perf.
-1.00%
1M flows
-€70M
AuM
€984M
E/R
0.75%
Rating
Not rated
ESG Consensus®
ARKG
$27.67
Performance & flows
Segment for quartile rank
December 9, 2025 → March 9, 2026
Create a free account to view the flows graph
ARKG
$28.79
-6.62%
BioTech & Genomics
-3.45%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -1.00%  | -6.62%  | +31.18% | +0.39% | -67.04% | -3.90% | -1.38% | -1.38%  | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
3/9/2026
$28.79
1D NAV change
+2.37%
Dividend policy
No. of holdings
30
Inception date
4/2/2019
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Management Investment Company
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSimilar ETFs in your region
AAKG
1M perf.
-3.78%
E/R
0.75%
XBI
1M perf.
+1.75%
E/R
0.35%
CURE
1M perf.
+0.85%
E/R
0.45%
XHE
1M perf.
-5.57%
E/R
0.35%
PSCH
1M perf.
-4.57%
E/R
0.29%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -6.62% | +31.18% | +0.39% | -67.04% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Countries
USA
73.95%
Switzerland
8.01%
Unavailable
17.06%
Other
0.98%
Sectors
Health Care
80.46%
Unavailable
18.56%
Other
0.98%
Diversification
Total weight of top 15 holdings out of 30
Top 15 holdings
Data as of January 31, 2026
CRISPR THERAPEUTICS
PERSONALIS INC
GUARDANT HEALTH INC
10X GENOMICS INC
BEAM THERAPEUTICS
ILLUMINA
NATERA
RECURSION PHARMACEUTICALS
Create a free account to view top holdings
CAREDX INC/D
VERACYTE INC/D
ADAPTIVE BIOTECHNOLOGIES
INTELLIA THERAPEUTICS INC
ABSCI
IONIS PHARMACEUTICALS INC
SCHRODINGER
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
Ark Investment
Ark Investment ID Card
Number of funds
10
Total AuM
€11.34B
Expense ratio range
0.49% - 0.89%
Average expense ratio
0.745%
Top 5 funds by Ark Investment
| AuM | ||
|---|---|---|
ARKK | ARK Innovation ETF | €5.7B |
ARKQ | ARK Autonomous Technology & Robotics ETF | €1.71B |
ARKW | ARK Next Generation Internet ETF | €1.42B |
ARKG | ARK Genomic Revolution ETF | €984M |
ARKF | ARK Blockchain & Fintech Innovation ETF | €734M |
Frequently asked questions about ARKG
What does ARK Genomic Revolution ETF, ARKG, invest in?
ARKG is a Active ETF. This ETF provides exposure to Other Equities.
What is the Total Expense ratio (TER) of ARKG?
ARKG carries a total expense ratio (TER) of 0.75%, indicating the annual cost for holding the fund.
When was ARKG launched?
ARKG was introduced to the market on April 2, 2019. It trades on United States
Who is the ETF issuer of ARKG?
ARK Genomic Revolution ETF, ARKG, is provided by Ark Investment. Learn more about Ark Investment here.
What is the current assets under management (AUM) of ARKG?
ARKG oversees €984M in assets as of March 9, 2026.
How has ARKG performed lately?
Based on data from March 9, 2026, ARKG returned -1.00% over the past month, -6.62% over the last three months and -1.38% year-to-date.
What are the latest inflows or outflows for ARKG?
As of March 9, 2026, ARKG recorded net flows of -€71M over the last month and -€13M year-to-date.
Does ARKG distribute dividends?
ARKG follows a distributing dividend policy, meaning it pays out income to investors.
What are the main country or region exposures of ARKG?
As of January 31, 2026, ARKG has significant geographic allocations in USA and Switzerland.
In which sector or theme does ARKG invest in?
As of January 31, 2026, ARKG focuses largely on Health Care.
How many securities does ARKG hold and how diversified is it?
As of January 31, 2026, ARKG holds 30 positions in its portfolio, with 63.79% of assets concentrated in its top 15 holdings.
What are the main positions in ARKG?
As of January 31, 2026, ARKG top three holdings include CRISPR THERAPEUTICS, PERSONALIS INC and GUARDANT HEALTH INC.
What is the base currency of ARKG?
The base currency of ARKG is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
